Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.03), Zacks reports. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.
Werewolf Therapeutics Price Performance
Shares of HOWL opened at $1.23 on Tuesday. The company has a 50 day moving average price of $1.38 and a 200-day moving average price of $1.83. Werewolf Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $6.89. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The stock has a market capitalization of $54.59 million, a PE ratio of -0.80 and a beta of 0.37.
Analyst Ratings Changes
Several analysts recently weighed in on HOWL shares. JMP Securities cut their price target on Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating on the stock in a research note on Tuesday, January 14th. HC Wainwright reiterated a "buy" rating and issued a $15.00 price target on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.
View Our Latest Report on Werewolf Therapeutics
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Werewolf Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Werewolf Therapeutics wasn't on the list.
While Werewolf Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
